4.6 Article

The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment

Journal

CANCERS
Volume 14, Issue 6, Pages -

Publisher

MDPI
DOI: 10.3390/cancers14061585

Keywords

reactive oxygen species (ROS); oxidative stress; chemotherapy; targeted agents; (in)fertility

Categories

Funding

  1. Unit for Multidisciplinary Research in Biomedicine (UMIB) - Foundation for Science and Technology (FCT) Portugal [UIDB/00215/2020, UIDP/00215/2020]
  2. ITR-Laboratory for Integrative and Translational Research in Population Health [LA/P/0064/2020]
  3. Portuguese Government
  4. European Union [DL57/2016/CP1327/CT0006]

Ask authors/readers for more resources

Tumor cells exhibit high resistance to oxidative stress, but excessive oxidative stress beyond a certain threshold can lead to cell death. Inducing imbalance in redox homeostasis can be a strategy in anticancer therapies, but the mechanisms behind the loss of fertility are still unknown. With the increasing life expectancy of cancer patients, it is important to consider the potential adverse effects of anticancer treatments on reproductive capacity.
Simple Summary Tumor cells are highly resistant to oxidative stress, but beyond a certain threshold, it may lead to apoptosis/necrosis. Thus, induced loss of redox balance can be a strategy used in anticancer therapies. However, the effectiveness of drugs contrasts with unknown mechanisms involved in the loss of fertility. Considering that cancer patients' life expectancy is increasing, it raises concerns about the unknown adverse effects. Therefore, new strategies should be pursued alongside explaining to the patients their options regarding the reproduction side effects. Tumor cells are highly resistant to oxidative stress resulting from the imbalance between high reactive oxygen species (ROS) production and insufficient antioxidant defenses. However, when intracellular levels of ROS rise beyond a certain threshold, largely above cancer cells' capacity to reduce it, they may ultimately lead to apoptosis or necrosis. This is, in fact, one of the molecular mechanisms of anticancer drugs, as most chemotherapeutic treatments alter redox homeostasis by further elevation of intracellular ROS levels or inhibition of antioxidant pathways. In traditional chemotherapy, it is widely accepted that most therapeutic effects are due to ROS-mediated cell damage, but in targeted therapies, ROS-mediated effects are mostly unknown and data are still emerging. The increasing effectiveness of anticancer treatments has raised new challenges, especially in the field of reproduction. With cancer patients' life expectancy increasing, many aiming to become parents will be confronted with the adverse effects of treatments. Consequently, concerns about the impact of anticancer therapies on reproductive capacity are of particular interest. In this review, we begin with a short introduction on anticancer therapies, then address ROS physiological/pathophysiological roles in both male and female reproductive systems, and finish with ROS-mediated adverse effects of anticancer treatments in reproduction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available